[1]陈昆山,张 靖,申 刚,等.经导管动脉化疗栓塞在中晚期肝胚细胞瘤术前的临床应用[J].介入放射学杂志,2016,(03):220-224.
　CHEN Kun- shan,ZHANG Jing,SHEN Gang,et al.Clinical application of preoperative transcatheter arterial chemoembolization in treating advanced hepatoblastomas[J].journal interventional radiology,2016,(03):220-224.
点击复制

经导管动脉化疗栓塞在中晚期肝胚细胞瘤术前的临床应用 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年03期
页码:
220-224
栏目:
肿瘤介入
出版日期:
2016-03-25

文章信息/Info

Title:
Clinical application of preoperative transcatheter arterial chemoembolization in treating advanced hepatoblastomas
作者:
陈昆山;  张 靖;  申 刚;  周少毅;  李海波;  牛传强;  谭小云;  姜 华
Author(s):
CHEN Kun- shan;  ZHANG Jing;  SHEN Gang;  ZHOU Shao- yi;  LI Hai- bo;  NIU Chuan- qiang;  TAN Xiao- yun;  JIANG Hua
Department of Interventional Therapy and Vascular Anomalies， Guangzhou Women and Children’s Medical Center， Guangzhou， Guangdong Province 510623， China
关键词:
【关键词】 经导管动脉化疗栓塞术;  肝胚细胞瘤;  临床应用;  新辅助化疗
文献标志码:
A
摘要:
【摘要】 目的 探讨TACE在中晚期肝胚细胞瘤切除术前治疗的疗效及安全性。方法 回顾性分析确诊的不能一期手术切除的肝胚细胞瘤患儿20例的临床资料，经导管对肿瘤供血动脉行顺铂和吡柔比星碘化油乳化液灌注并作聚乙烯醇泡沫颗粒或微球栓塞，术后4周复查胸腹部CT及AFP。如肿瘤仍无法切除继续TACE，直至肿瘤缩小至适合切除，观察患儿的临床疗效、PRETEXT分期变化、并发症、手术中情况及肿瘤坏死面积，并对远期效果随访。结果 本组患儿共行TACE治疗49次，肿瘤体积缩小达56.2%~91.6%，平均68%（t=8.418，P<0.001），AFP降低达91.4%~99.9%，平均99.2%（t=2．531，P=0.02），PRETEXT分期下降，TACE后未出现严重并发症和不良反应，20例患儿均重新获得手术机会，术中肿瘤易于切除，切除肿瘤标本显示肿瘤坏死面积达63.7%~91.9%，平均82.9%。远期随访，肿瘤切除术后死于肺转移2例、复发1例，17例患儿无瘤存活时间平均21.9个月，随访时间6~48个月。结论 TACE能显著使肝胚细胞瘤瘤体缩小并AFP下降，使中晚期肝胚细胞瘤患儿重新获得手术切除机会，是一种安全、有效的治疗方法。

参考文献/References:

［1］ 李家平， 杨建勇， 陈 伟， 等． 术前经动脉化疗栓塞在肝胚细胞瘤治疗中的应用［J］． 中华肝胆外科杂志， 2004， 10： 597- 601．
［2］ Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary liver of childhood developed by the SIOPEL group［J］. Pediatr Radiol, 2007, 37, 123- 132.
［3］ 李 龙， 陈 勇， 李彦豪， 等． 经导管动脉化疗栓塞术治疗肝胚细胞瘤［J］． 中华肝脏病杂志， 2004， 12： 48- 49．
［4］ 李长春， 金先庆． 儿童肝胚细胞瘤诊治进展［J］． 重庆医学， 2007， 36： 1481- 1482．
［5］ Ablin A, Plaschkes J. A perspective on the hepatoblastoma sympo- sium［J］. Pediatr Blood Cancer, 2012, 59: 775.
［6］ Haberle B, Bode U, Von Schweinitz D. Differentiated treatment protocols for high- and standard- risk hepatoblastoma: an interim report of the German Liver Tumor Study HB99［J］. Klin Padiatr, 2003, 215: 159- 165.
［7］ Schnater JM, Kohler SE, Lamers WH, et al. Where do we stand with hepatoblastoma? A review［J］. Cancer, 2003, 98: 668- 678.
［8］ Ismail H, Broniszczak D, Kalicinski P, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years［J］. J Pediatr Surg, 2012, 47: 1331- 1339.
［9］ Perilongo G, Malogolowkin M, Feusner J. Hepatoblastoma clinical research: lessons learned and future challenges［J］. Pediatr Blood Cancer, 2012, 59: 818- 821.
［10］ Von Schweinitz D. Hepatoblastoma: recent developments in research and treatment［J］. Semin Pediatr Surg, 2012, 21: 21- 30.
［11］ Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival［J］. Surgery, 1970, 68: 383- 388.
［12］ Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group［J］. Pediatr Radiol, 2007, 37: 123- 132.
［13］ Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation［J］. J Pediatr, 2005, 146: 204- 211.
［14］ 钭金法， 王金湖， 熊启星， 等． 不可切除型肝胚细胞瘤的术前介入治疗临床研究［J］． 中华小儿外科杂志， 2006， 27： 341- 344．
［15］ Zhang J, Xu F, Chen K, et al. An effective approach for treating unresectable hepatoblastoma in infants and children: pre- operative transcatheter arterial chemoembolization［J］. Oncol Lett, 2013, 6: 850- 854.
［16］ Tan X, Zhang J, Wen Z, et al. Preoperative transcatheter arterial chemoembolization of hepatoblastoma in infants［J］. J Vasc Interv Radiol, 2014, 25: 1029- 1035.
［17］ Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era: recommendations from the Childhood Liver Tumour Strategy Group of the Inter- national Society of Paediatric Oncology（SIOPEL）［J］. Eur J Cancer, 2005, 41: 1031- 1036.
［18］ Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience［J］. Eur J Cancer, 2012, 48: 1543- 1549.
［19］ 刘 方， 张俊义， 邢纪中． 小儿肝恶性肿瘤肝动脉介入治疗［J］． 临床儿科杂志， 2000， 18： 328- 329．
［20］ Fuchs J, Rydzynski J, Hecker H, et al. The influence of preope- rative chemotherapy and surgical technique in the treatment of hepatoblastoma: a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94［J］. Eur J Pediatr Surg, 2002, 12: 255- 261.
［21］ Shi M, Zhang X, Wang P, et al. TIP30 regulates apoptosis- related genes in its apoptotic signal transduction pathway［J］. World J Gastroenterol, 2005, 11: 221- 227.
［22］ Ohtsuka Y, Matsunaga T, Yoshida H, et al. Optimal strategy of preoperative transcatheter arterial chemoembolization for hepato- blastoma［J］. Surg Today, 2004, 34: 127- 133.

相似文献/References:

[1]张 雯,周永杰,颜志平.再论精细TACE[J].介入放射学杂志,2021,30(10):971.
　ZHANG Wen,ZHOU Yongjie,YAN Zhiping..Further discussion on the precision TACE therapy[J].journal interventional radiology,2021,30(03):971.
[2]姜小庆,黄 鹏,胡 波,等.动脉栓塞药物洗脱微球的研究进展[J].介入放射学杂志,2023,32(10):1034.
　JIANG Xiaoqing,HUANG Peng,HU Bo,et al.Research progress in drug-eluting beads used for transarterial chemoembolization[J].journal interventional radiology,2023,32(03):1034.
[3]张学贤,丁雨寒,李 威,等.经导管动脉化疗栓塞联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌临床效果[J].介入放射学杂志,2024,33(01):57.
　ZHANG Xuexian,DING Yuhan,LI Wei,et al.Clinical efficacy of transcatheter arterial chemoembolization combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma[J].journal interventional radiology,2024,33(03):57.
[4]余 磊,邹春峰,苏孙欢,等.经导管动脉化疗栓塞术治疗局部复发乳腺癌的疗效与安全性[J].介入放射学杂志,2024,33(03):280.
　YU Lei,ZOU Chunfeng,SU Sunhuan,et al.Efficacy and safety of transcatheter arterial chemoembolization for the treatment of locally recurrent breast cancer[J].journal interventional radiology,2024,33(03):280.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０6-26）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-03-22